Arkema Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 4/6
Arkema hat ein Gesamteigenkapital von €7.0B und eine Gesamtverschuldung von €4.2B, wodurch sich der Verschuldungsgrad auf 59.7% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen €14.2B bzw. €7.2B. Arkema Das EBIT des Unternehmens beträgt €404.0M, so dass der Zinsdeckungsgrad 5.3 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von €2.2B.
Wichtige Informationen
59.73%
Verhältnis von Schulden zu Eigenkapital
€4.20b
Verschuldung
| Zinsdeckungsgrad | 5.3x |
| Bargeld | €2.19b |
| Eigenkapital | €7.03b |
| Gesamtverbindlichkeiten | €7.21b |
| Gesamtvermögen | €14.25b |
Jüngste Berichte zur Finanzlage
Recent updates
AKE: Battery Materials Expansion Will Support Future Rerating Potential
Arkema's analyst fair value estimate has moved slightly higher to about €81.56, reflecting analysts' updated assumptions on revenue growth, profit margins, and future P/E in light of recent upgrades, downgrades, and modest price target increases from several banks. Analyst Commentary Recent Street research on Arkema is mixed, but there is a clear cluster of more constructive calls that help frame how supportive analysts currently see the risk and reward around the stock.
AKE: Battery Expansion And Margin Execution Will Constrain Future Re Rating Potential
Arkema's fair value estimate has shifted from €44.00 to €50.00 as analysts factor in updated assumptions on revenue growth, profit margins and future P/E multiples, in line with a recent series of higher price targets and rating changes across major research firms. Analyst Commentary Recent Street research on Arkema presents a mixed picture, with several higher price targets sitting alongside at least one downgrade and more restrained views on upside.AKE: Battery Capacity Push Will Face Execution Risk And Uncertain Earnings Trajectory
Analysts have nudged Arkema's average price target higher to around €60 to €65, citing recent target increases from several banks and mixed rating changes that reflect a more balanced view on growth, margins, and a higher assumed future P/E multiple. Analyst Commentary Recent research has given Arkema a more mixed backdrop, with some banks lifting price targets while others turn more cautious on the shares, despite keeping targets within a relatively tight €60 to €65 range.
AKE: Battery Materials Expansion And Mixed Ratings Will Shape Future Rerating
Arkema's analyst price target has edged up by €0.13 to €61.88, reflecting a blend of higher fair value P/E assumptions and mixed rating actions from analysts who have recently adjusted targets between €60 and €65. Analyst Commentary Bullish Takeaways Bullish analysts are comfortable assigning price targets in the €62 to €65 range, which supports the current blended target of €61.88 and signals confidence that Arkema can justify a slightly higher P/E than previously assumed.AKE: Battery Materials Expansion And Decarbonization Efforts Will Support Future Rerating
Our analyst price target for Arkema shifts from €65.06 to €61.88 as analysts factor in recent downgrades and lower external price targets, along with updated assumptions for revenue growth, profit margins and future P/E multiples. Analyst Commentary Recent Street research on Arkema has been mixed, with both upgrades and downgrades sitting alongside reduced price targets.AKE: Battery Materials And Specialty Polymers Will Support Re Rating
Arkema's analyst price target has shifted from €85.00 to €80.00, as analysts factor in slightly softer assumptions on revenue growth, profit margins and future P/E, even as recent research updates include both an upgrade and a separate €5 adjustment to targets. Analyst Commentary Recent research on Arkema sends a mixed but broadly constructive signal, with the latest changes in price targets and ratings pointing to a more nuanced view of the company’s risk and reward profile.After Leaping 26% Arkema S.A. (EPA:AKE) Shares Are Not Flying Under The Radar
Feb 13
AKE: Battery Expansion Will Face Tougher Sector Backdrop And Execution Risk
Analysts have trimmed their price target on Arkema by €5, reflecting softer revenue growth assumptions, a slightly lower future P/E multiple, and sector headwinds highlighted in recent research, while keeping fair value broadly unchanged. Analyst Commentary Recent research points to a more cautious tone around Arkema, with pricing assumptions and sector views putting some pressure on sentiment.AKE: Battery Materials Expansion Will Face Tougher Sector Backdrop And Execution Risk
Narrative update Analysts have trimmed their price target on Arkema by €3 to €44, reflecting a lower fair value estimate along with updated views on revenue growth, margins and a reduced future P/E multiple, following recent cautious research on European chemicals and ingredients groups. Analyst Commentary Street research on Arkema has turned more cautious, with bearish analysts trimming price targets and flagging risks around growth visibility and valuation.AKE: Battery Materials Push Will Support Re Rating Despite Sector Downgrade
Analysts have trimmed their fair value estimate for Arkema to €85 from €95. This reflects lower assumed revenue growth, a slightly softer profit margin profile, a higher discount rate and more conservative future P/E expectations following recent cuts to Street price targets and a sector downgrade.AKE: Battery Materials Push Will Confront Tougher Sector Backdrop Ahead
The analyst fair value estimate for Arkema has been reduced from EUR 56 to EUR 47 as analysts factor in a higher discount rate, weaker revenue growth expectations, softer profit margins, and a sector wide shift toward more favored industrial gases and specialty distributors. Analyst Commentary Recent Street research reflects a more cautious stance on Arkema, with several bearish analysts trimming price targets and, in at least one case, reducing their rating.AKE: Sustainability And Decarbonization Investments Will Drive Future Rerating Despite Recent Downgrade
Arkema's analyst price target has been trimmed by about EUR 1 to EUR 65.06 as analysts factor in slightly softer long term growth and margin expectations, alongside a wave of recent price target cuts and a fresh Underweight rating from the Street. Analyst Commentary Recent Street research presents a mixed picture for Arkema, with several price target cuts but divergent views on the company’s medium term execution and earnings power.AKE: Recent Downgrade Will Be Offset By Sustainability Actions And Emissions Reductions
Analysts have lowered the fair value estimate for Arkema from €70.63 to €66.06, citing cautious sector sentiment and a series of reduced price targets across the chemical industry. Analyst Commentary Analysts continue to reassess Arkema's prospects in response to both company-specific and broader sector developments.There May Be Reason For Hope In Arkema's (EPA:AKE) Disappointing Earnings
Nov 16Arkema S.A. (EPA:AKE) Just Reported, And Analysts Assigned A €66.94 Price Target
Nov 12AKE: Operational Improvements And Sustainability Efforts Will Drive Future Upside
The consensus analyst price target for Arkema has been reduced notably in recent updates, with targets now ranging from EUR 55 to EUR 80. Analysts cite cautious expectations for revenue growth and refining profit margin assumptions as reasons for the adjustment.Analysts Revise Arkema Price Target Lower Amid Cautious Optimism and Recent Sustainability Initiatives
Arkema's analyst price target has been revised downward from €72.75 to €70.63. This change reflects recent analyst adjustments driven by lower growth and profit expectations.New Capacity And R&D Focus Will Accelerate Renewable Transition
Arkema's analyst price target has been revised downward from €76.06 to €72.75. This change reflects analysts' expectations for slower revenue growth and a higher discount rate, even though profit margins have seen slight improvement.New Capacity And R&D Focus Will Accelerate Renewable Transition
Analysts have trimmed Arkema’s price target to €76.06, reflecting heightened caution around 2025 guidance cuts, persistent margin pressure, and weaker end-market demand, despite some confidence in the company’s long-term positioning. Analyst Commentary Bearish analysts cite increased risk of significant 2025 guidance cuts, particularly ahead of Q2 results.Is It Too Late To Consider Buying Arkema S.A. (EPA:AKE)?
Aug 27Arkema S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 06These 4 Measures Indicate That Arkema (EPA:AKE) Is Using Debt Reasonably Well
Jul 27Potential Upside For Arkema S.A. (EPA:AKE) Not Without Risk
Jul 05Arkema (EPA:AKE) Is Increasing Its Dividend To €3.60
May 23Arkema S.A. Just Missed EPS By 78%: Here's What Analysts Think Will Happen Next
May 10Arkema (EPA:AKE) Is Paying Out A Larger Dividend Than Last Year
May 07What Is Arkema S.A.'s (EPA:AKE) Share Price Doing?
May 02
Specialty Materials And Renewable Energy Initiatives Ignite Earnings Growth And Margin Expansion
Strategic projects and acquisitions aim to enhance Arkema's earnings growth and stability, leveraging mega trends in energy and healthcare.Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: AKEDie kurzfristigen Aktiva des Unternehmens (€4.8B) übersteigen seine kurzfristigen Passiva (€2.3B).
Langfristige Verbindlichkeiten: AKEDie kurzfristigen Vermögenswerte des Unternehmens (€4.8B) decken seine langfristigen Verbindlichkeiten (€5.0B) nicht.
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: AKEDie Nettoverschuldung im Verhältnis zum Eigenkapital (28.6%) wird als zufriedenstellend angesehen.
Schulden abbauen: AKEDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 50.5% auf 59.7% gestiegen.
Schuldendeckung: AKEDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (23.7%).
Zinsdeckung: AKEDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (5.3x Coverage) gut gedeckt.
Bilanz
Entdecken Sie finanziell stabile Unternehmen
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/02 05:30 |
| Aktienkurs zum Tagesende | 2026/04/30 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Arkema S.A. wird von 32 Analysten beobachtet. 15 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Gaurav Jain | Barclays |
| Katie Richards | Barclays |
| James Stewart | Barclays |